What is the share price of Rekvina Laboratories Ltd (VINRKLB) today?
The share price of VINRKLB as on 28th January 2026 is ₹10.94. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Rekvina Laboratories Ltd (VINRKLB) share?
The past returns of Rekvina Laboratories Ltd (VINRKLB) share are- Past 1 week: 21.42%
- Past 1 month: 62.07%
- Past 3 months: N/A%
- Past 6 months: 54.52%
- Past 1 year: 54.52%
- Past 3 years: N/A%
- Past 5 years: 54.52%
What are the peers or stocks similar to Rekvina Laboratories Ltd (VINRKLB)?
The peers or stocks similar to Rekvina Laboratories Ltd (VINRKLB) include:What is the market cap of Rekvina Laboratories Ltd (VINRKLB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Rekvina Laboratories Ltd (VINRKLB) is ₹6.28 Cr as of 28th January 2026.What is the 52 week high and low of Rekvina Laboratories Ltd (VINRKLB) share?
The 52-week high of Rekvina Laboratories Ltd (VINRKLB) is ₹10.94 and the 52-week low is ₹6.75.What is the PE and PB ratio of Rekvina Laboratories Ltd (VINRKLB) stock?
The P/E (price-to-earnings) ratio of Rekvina Laboratories Ltd (VINRKLB) is -44.87. The P/B (price-to-book) ratio is -18.47.Which sector does Rekvina Laboratories Ltd (VINRKLB) belong to?
Rekvina Laboratories Ltd (VINRKLB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Rekvina Laboratories Ltd (VINRKLB) shares?
You can directly buy Rekvina Laboratories Ltd (VINRKLB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Rekvina Laboratories Ltd
VINRKLB Share Price
10.944.99% (+0.52)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
VINRKLB Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
BadThe stock is in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
VINRKLB Performance & Key Metrics
VINRKLB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -48.32 | -18.47 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 34.67 | 5.50 | 0.62% |
VINRKLB Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
VINRKLB Company Profile
Rekvina Laboratories is engaged in business of pharmaceuticals.
SUNPHARMA
PE Ratio
35.98
35.98
1Y Return
5.56%
5.56%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
70.79
70.79
1Y Return
19.43%
19.43%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
20.12
20.12
1Y Return
6.49%
6.49%
Buy Reco %
58.06
58.06
DRREDDY
PE Ratio
18.25
18.25
1Y Return
3.49%
3.49%
Buy Reco %
50.00
50.00
LUPIN
PE Ratio
29.93
29.93
1Y Return
5.30%
5.30%
Buy Reco %
72.22
72.22
VINRKLB Forecast
VINRKLB Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
VINRKLB
VINRKLB
Income
Balance Sheet
Cash Flow
Annual Normal View
VINRKLB Income Statement
VINRKLB Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.03 | 0.02 | 0.01 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | ||||||||||
Raw Materials | 0.05 | 0.10 | 0.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.33 | ||||||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||
| Employee Cost | 0.08 | 0.00 | 0.00 | 0.00 | 0.04 | |||||||||||||||
| Selling & Administrative Expenses | 0.03 | 0.04 | 0.08 | 0.02 | 0.07 | |||||||||||||||
| Operating & Other expenses | 0.04 | 0.02 | 0.00 | 0.00 | 0.03 | |||||||||||||||
EBITDA | -0.02 | -0.08 | -0.25 | 0.00 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.13 | ||||||||||
| Depreciation/Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| PBIT | -0.02 | -0.08 | -0.25 | 0.00 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.13 | ||||||||||
| Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| PBT | -0.02 | -0.08 | -0.25 | 0.00 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.13 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Net Income | -0.02 | -0.08 | -0.25 | 0.00 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.13 | ||||||||||
| EPS | -0.03 | -0.13 | -0.42 | 0.00 | -0.10 | -0.13 | 0.00 | -0.03 | -0.23 | -0.22 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
VINRKLB Company Updates
VINRKLB Stock Peers
VINRKLB Past Performance & Peer Comparison
VINRKLB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Rekvina Laboratories Ltd | -44.87 | -18.47 | — |
| Sun Pharmaceutical Industries Ltd | 35.98 | 5.42 | 0.98% |
| Torrent Pharmaceuticals Ltd | 70.79 | 17.82 | 0.80% |
| Cipla Ltd | 20.12 | 3.39 | 1.22% |
VINRKLB Stock Price Comparison
Compare VINRKLB with any stock or ETFCompare VINRKLB with any stock or ETF
VINRKLB
VINRKLB Holdings
VINRKLB Shareholdings
VINRKLB Promoter Holdings Trend
VINRKLB Promoter Holdings Trend
VINRKLB Institutional Holdings Trend
VINRKLB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
VINRKLB Shareholding Pattern
VINRKLB Shareholding Pattern
VINRKLB Shareholding History
VINRKLB Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing VINRKLB stock
smallcases containing VINRKLB stock
Looks like this stock is not in any smallcase yet.
VINRKLB Events
VINRKLB Events
VINRKLB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VINRKLB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
VINRKLB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VINRKLB has not given any dividends in last 5 years
VINRKLB Dividends
VINRKLB Dividends
Hmm, looks like data is unavailable here. Please come back after some timeVINRKLB Stock News & Opinions
VINRKLB Stock News & Opinions
Articles & Videos
Earnings
Rekvina Labs reports standalone net loss of Rs 0.02 crore in the December 2024 quarter
Net loss of Rekvina Labs reported to Rs 0.02 crore in the quarter ended December 2024. There were no net profit/loss reported during the previous quarter ended December 2023. There were no Sales reported in the quarter ended December 2024 and during the previous quarter ended December 2023.Powered by Capital Market - Live
1 year agoCapital Market - Live
Corporate
Rekvina Labs to discuss results
Rekvina Labs will hold a meeting of the Board of Directors of the Company on 20 January 2025.Powered by Capital Market - Live
1 year agoCapital Market - Live
Earnings
Rekvina Labs reports standalone net loss of Rs 0.07 crore in the September 2024 quarter
Net Loss of Rekvina Labs reported to Rs 0.07 crore in the quarter ended September 2024 as against net loss of Rs 0.01 crore during the previous quarter ended September 2023. There were no Sales reported in the quarter ended September 2024 and during the previous quarter ended September 2023.Powered by Capital Market - Live
1 year agoCapital Market - Live
Corporate
Rekvina Labs to table results
Rekvina Labs will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
1 year agoCapital Market - Live
Corporate
Rekvina Labs AGM scheduled
Rekvina Labs announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
1 year agoCapital Market - Live
Corporate
Rekvina Labs revises board meeting date
Rekvina Labs has revised the meeting of the Board of Directors which was scheduled to be held on 30 August 2024. The meeting will now be held on 2 September 2024.Powered by Capital Market - Live
1 year agoCapital Market - Live
Corporate
Rekvina Labs to conduct board meeting
Rekvina Labs will hold a meeting of the Board of Directors of the Company on 30 August 2024.Powered by Capital Market - Live
1 year agoCapital Market - Live
Corporate
Rekvina Labs revises AGM Date
Rekvina Labs has revised the Annual General Meeting (AGM) of the company which was scheduled to held on 5 August 2024. The meeting will now be held on 12 August 2024.Powered by Capital Market - Live
1 year agoCapital Market - Live
Earnings
Rekvina Labs reports standalone nil net profit/loss in the June 2024 quarter
Rekvina Labs reported no net profit/loss in the quarter ended June 2024 and during the previous quarter ended June 2023. There were no Sales reported in the quarter ended June 2024 and during the previous quarter ended June 2023.Powered by Capital Market - Live
1 year agoCapital Market - Live
Corporate
Rekvina Labs schedules board meeting
Rekvina Labs will hold a meeting of the Board of Directors of the Company on 29 July 2024.Powered by Capital Market - Live
1 year agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant